Remdesivir for COVID-19 linked to better outcomes for adult kidney transplant recipients
Adults with kidney transplants who were treated for COVID-19 with the antiviral remdesivir within a week of a COVID-19 diagnosis and who received at least three consecutive days of therapy were less likely than kidney transplant recipients who did not receive the antiviral to experience cardiovascul
<p>Adults with kidney transplants who were treated for COVID-19 with the antiviral remdesivir within a week of a COVID-19 diagnosis and who received at least three consecutive days of therapy were less likely than kidney transplant recipients who did not receive the antiviral to experience cardiovascul</p>